{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:00:32Z","timestamp":1784926832743,"version":"3.55.0"},"reference-count":135,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Non\u2013small-cell lung cancer (NSCLC) has seen a paradigm shift over the past quarter century driven by systematic molecular characterization, the advent of targeted therapies, the implementation of low-dose CT screening, and the integration of immunotherapy across the disease continuum. Genomic profiling has defined oncogene-addicted subsets for which targeted agents now improve survival in both metastatic and resectable disease, while immune checkpoint inhibitors have displaced chemotherapy as first-line treatment for many patients without actionable drivers and have been incorporated into perioperative and consolidation strategies. Concurrently, adjuvant and consolidation tyrosine kinase inhibition has extended precision oncology into early-stage\n                    <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                    - and\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    -driven NSCLC. Here, we review pivotal therapeutic advances across metastatic, locally advanced, and early-stage disease; identify the need for more discriminating markers to refine treatment intensity and sequencing; and outline emerging approaches, including rational upfront combinations and the use of circulating tumor DNA to enable real-time, adaptive modulation of therapy in NSCLC.\n                  <\/jats:p>","DOI":"10.1097\/ppo.0000000000000834","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:17Z","timestamp":1784923217000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Quarter Century of Transformation: Integrating Molecular Stratification and Immune Modulation Across the Continuum of Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-9105","authenticated-orcid":false,"given":"Amin H.","family":"Nassar","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Halawi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260724","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"R2-20260724","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group","volume":"311","year":"1995","journal-title":"Brit Med J"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"823618","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front Immunol"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"R7-20260724","first-page":"e14","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"379","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated alk-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20260724","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced alk-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jtho.2025.06.028","article-title":"50 years of progress in NSCLC: a new fellow\u2019s guide in the clinic","volume":"20","author":"Naidoo","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-20260724","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13073-022-01041-x","article-title":"Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology","volume":"14","author":"Adib","year":"2022","journal-title":"Genome Med"},{"key":"R22-20260724","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"R24-20260724","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J Clin Oncol"},{"key":"R25-20260724","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N Engl J Med"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"R28-20260724","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"R29-20260724","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"R30-20260724","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"R31-20260724","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"R32-20260724","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jtho.2023.09.033","article-title":"OA03.04 A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions","volume":"18","author":"Han","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R33-20260724","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.00152","article-title":"Safety, tolerability, and antitumor activity of zipalertinib among patients with non\u2013small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J Clin Oncol"},{"key":"R34-20260724","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R35-20260724","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"R36-20260724","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41571-024-00979-8","article-title":"Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions","volume":"22","author":"Wang","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R37-20260724","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R38-20260724","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R39-20260724","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"R40-20260724","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R41-20260724","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"R42-20260724","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"R43-20260724","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"R44-20260724","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol"},{"key":"R45-20260724","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R46-20260724","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R47-20260724","doi-asserted-by":"crossref","first-page":"100273","DOI":"10.1016\/j.esmoop.2021.100273","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update","volume":"6","author":"Reck","year":"2021","journal-title":"ESMO Open"},{"key":"R48-20260724","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"R49-20260724","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"R50-20260724","doi-asserted-by":"crossref","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"R51-20260724","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-020-00881-7","article-title":"Emerging therapeutic agents for advanced non-small cell lung cancer","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R52-20260724","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"R53-20260724","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"R54-20260724","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"R55-20260724","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"R56-20260724","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"R57-20260724","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"R58-20260724","doi-asserted-by":"crossref","first-page":"120ra117","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"R59-20260724","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.annonc.2025.09.018","article-title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study","volume":"37","author":"Peters","year":"2026","journal-title":"Ann Oncol"},{"key":"R60-20260724","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"R61-20260724","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial","volume":"18","author":"Yang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R62-20260724","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"R63-20260724","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"key":"R64-20260724","first-page":"100909","article-title":"Crizotinib in patients with ROS1-positive NSCLC with or without brain metastases: post hoc analysis of phase II METROS trial","volume":"6","author":"Landi","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"R65-20260724","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"key":"R66-20260724","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1200\/JCO-25-01055","article-title":"Taletrectinib in ROS1 fusion-positive non-small cell lung cancer: promising yet premature?","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"R67-20260724","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"R68-20260724","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers - biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R69-20260724","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrclinonc.2017.188","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R70-20260724","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"R71-20260724","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"R72-20260724","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET Fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"R73-20260724","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat Commun"},{"key":"R74-20260724","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol"},{"key":"R75-20260724","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R76-20260724","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jtho.2025.05.023","article-title":"Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC-a brief report","volume":"20","author":"Riely","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R77-20260724","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"key":"R78-20260724","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"R79-20260724","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"R80-20260724","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"R81-20260724","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"R82-20260724","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/2159-8290.CD-25-0349","article-title":"Response and resistance to RAS inhibition in cancer","volume":"15","author":"Ebright","year":"2025","journal-title":"Cancer Discov"},{"key":"R83-20260724","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"R84-20260724","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"R85-20260724","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO-25-00040","article-title":"Single-agent divarasib in patients with KRAS G12C-positive non-small cell lung cancer: long-term follow-up of a phase I study","volume":"43","author":"Sacher","year":"2025","journal-title":"J Clin Oncol"},{"key":"R86-20260724","doi-asserted-by":"crossref","first-page":"TPS9158","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9158","article-title":"A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression \u22651% and an STK11 co-mutation","volume":"41","author":"Lindsay","year":"2023","journal-title":"J Clin Oncol"},{"key":"R87-20260724","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1200\/JCO.2024.42.16_suppl.8510","article-title":"Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC","volume":"42","author":"Burns","year":"2024","journal-title":"J Clin Oncol"},{"key":"R88-20260724","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"R89-20260724","doi-asserted-by":"crossref","first-page":"CT019","DOI":"10.1158\/1538-7445.AM2025-CT019","article-title":"Abstract CT019: preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors","volume":"85","author":"Arbour","year":"2025","journal-title":"Cancer Res"},{"key":"R90-20260724","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"key":"R91-20260724","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in advanced HER2-mutant non-small-cell lung cancer","volume":"393","author":"Le","year":"2025","journal-title":"N Engl J Med"},{"key":"R92-20260724","first-page":"403","article-title":"Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC)","volume":"2","author":"Liang","year":"2013","journal-title":"Transl Lung Cancer Res"},{"key":"R93-20260724","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"R94-20260724","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(14)61208-3","article-title":"Preoperative chemotherapy for non-small-cell lung cancer","volume":"384","author":"Hanna","year":"2014","journal-title":"Lancet"},{"key":"R95-20260724","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"R96-20260724","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"R97-20260724","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"R98-20260724","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"R99-20260724","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"R100-20260724","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"R101-20260724","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"R102-20260724","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"R103-20260724","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jtho.2024.09.1379","article-title":"Consolidation ALK tyrosine kinase inhibitors versus durvalumab or observation after chemoradiation in unresectable stage III ALK-positive NSCLC","volume":"20","author":"Nassar","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R104-20260724","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2024.06.008","article-title":"Prevalence of EGFR mutations in patients with resected stages I to III NSCLC: results from the EARLY-EGFR study","volume":"19","author":"Soo","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R105-20260724","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat Med"},{"key":"R106-20260724","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","article-title":"Therapeutic management options for stage III non-small cell lung cancer","volume":"8","author":"Yoon","year":"2017","journal-title":"World J Clin Oncol"},{"key":"R107-20260724","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2014.60.0130","article-title":"Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04","volume":"33","author":"Ahn","year":"2015","journal-title":"J Clin Oncol"},{"key":"R108-20260724","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R109-20260724","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"R110-20260724","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jtho.2023.02.009","article-title":"Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC","volume":"18","author":"Naidoo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R111-20260724","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jtho.2024.01.012","article-title":"Consolidation osimertinib versus durvalumab versus observation following concurrent chemoradiation in unresectable EGFR-mutant non-small-cell lung cancer: a multicenter retrospective cohort study","volume":"19","author":"Nassar","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R112-20260724","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"R113-20260724","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R114-20260724","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJMe2514042","article-title":"Navigating the evolving landscape of EGFR-mutated NSCLC","volume":"394","author":"Herbst","year":"2026","journal-title":"N Engl J Med"},{"key":"R115-20260724","doi-asserted-by":"crossref","first-page":"115624","DOI":"10.1016\/j.ejca.2025.115624","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: patient satisfaction and resource utilization results from the PALOMA-3 study","volume":"227","author":"Alexander","year":"2025","journal-title":"Eur J Cancer"},{"key":"R116-20260724","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol"},{"key":"R117-20260724","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"R118-20260724","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R119-20260724","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"R120-20260724","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41586-023-06953-1","article-title":"De novo design of high-affinity binders of bioactive helical peptides","volume":"626","author":"V\u00e1zquez Torres","year":"2024","journal-title":"Nature"},{"key":"R121-20260724","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s43018-025-00917-2","article-title":"Hallmarks of artificial intelligence contributions to precision oncology","volume":"6","author":"Chang","year":"2025","journal-title":"Nat Cancer"},{"key":"R122-20260724","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamaoncol.2024.5356","article-title":"Deep learning model for predicting immunotherapy response in advanced non-small cell lung cancer","volume":"11","author":"Rakaee","year":"2025","journal-title":"JAMA Oncol"},{"key":"R123-20260724","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop J"},{"key":"R124-20260724","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"R125-20260724","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2174\/0115680096360059250131075456","article-title":"Groundbreaking mRNA lung cancer vaccine trials: a new dawn in cancer treatment","volume":"25","author":"Hussain","year":"2025","journal-title":"Curr Cancer Drug Targets"},{"key":"R126-20260724","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.3390\/biomedicines13092187","article-title":"mRNA vaccines in modern immunotherapy for non-small cell lung cancer (NSCLC)-a comprehensive literature review with focus on current clinical trials","volume":"13","author":"Kabut","year":"2025","journal-title":"Biomedicines"},{"key":"R127-20260724","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","article-title":"ctDNA applications and integration in colorectal cancer: an NCI colon and rectal-anal task forces whitepaper","volume":"17","author":"Dasari","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R128-20260724","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"R129-20260724","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1038\/s41591-025-03983-2","article-title":"Generative artificial intelligence in medicine","volume":"31","author":"Teo","year":"2025","journal-title":"Nat Med"},{"key":"R130-20260724","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy\u2013are we making headway?","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R131-20260724","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-25-0999","article-title":"Epigenetic heritability of cell plasticity drives cancer drug resistance through a one-to-many genotype-to-phenotype paradigm","volume":"85","author":"Oliveira","year":"2025","journal-title":"Cancer Res"},{"key":"R132-20260724","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"R133-20260724","doi-asserted-by":"crossref","first-page":"102337","DOI":"10.1016\/j.xcrm.2025.102337","article-title":"From bench to body: in vivo CAR engineering in the clinic","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep Med"},{"key":"R134-20260724","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/d41573-024-00170-9","article-title":"Protein degraders push into novel target space","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"R135-20260724","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat Rev Cancer"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:31Z","timestamp":1784923231000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":135,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000834","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-01-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}